Pfizer CEO Albert Bourla on June 22 said the US-based drug maker is final stages to sign an agreement with Indian government to supply COVID-19 vaccines.
"We are discussing with India govt, we are in final stages of finalising agreement," Bourla said at the 15th annual BioPharma & Healthcare Summit, USA-India Chamber of Commerce (USAIC)
"We need to get approval of this vaccine in India. We are in a good way to get approval. Then we have to have a sign an agreement that will allow us to send doses," Bourla said.
Bourla said that Pfizer will be able to produce 3 billion vaccines by the end of 2021, and 4 billion vaccines in 2022.
Bourla said Pfizer has specific plans to meet the demand of COVID-19 vaccines for lower and middle income countries (LMIC) including India.
As part of the plan, LMIC countries will receive at least two billion doses of Pfizer's COVID-19 vaccines, and at least 1 billion of this will be this year alone.
Bourla said Pfizer recently concluded a deal with the US government, wherein US government purchases 500 million of COVID-19 doses at below the cost of production, and give to LMIC countries at free of cost.
"They're going to be 7 billions within two years.. beginning of next year.. the world will have a lot of vaccines available for all," Bourla said.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
